Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Behind Closed Doors: FDA Drug Safety Board Will Keep Its Decisions Private

Executive Summary

The pharmaceutical industry and other FDA stakeholders should not hold their breath waiting for more details about the agency's Drug Safety Oversight Board recommendations or the extent of internal debate and disagreement at its monthly non-public meetings

You may also be interested in...

FDA's Drug Safety Oversight Board Looks To Promote Its Value

FDA's Drug Safety Oversight Board is trying to promote its value to the medical and regulatory communities by highlighting its role in addressing postmarketing safety issues

Avandia Advisory Committee Re-Review Reflects Well On FDA

The FDA advisory committee re-review of cardiovascular safety risks with GlaxoSmithKline's Avandia (rosiglitazone) will not end calls from agency critics to create a separate drug safety center. However, the transparency of internal scientific disputes on display at the July 13-14 meeting and the committee's recommendations could take some ammunition away from those who assert the Center for Drug Evaluation and Research has given short shrift to safety issues

FDA Transparency Initiative: Disclosure Rules Could Expand, Then Be Harmonized

Following the release of FDA's Transparency Task Force report, the agency may want to add an agenda item to its harmonization discussions with EMA


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts